Losartan in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Guidance

What Is the FDA Approval Status of Losartan in Adolescents?

The FDA approved losartan (Cozaar) for pediatric hypertension in patients ages 6 and older in 2003, based on pharmacokinetic and efficacy data submitted by Merck. That approval covers oral solution and tablets at weight-based doses. Most prescribing in 12-to-17-year-olds for hypertension is therefore on-label.

The off-label territory in this age group includes three main indications: reduction of proteinuria in chronic kidney disease (CKD), slowing aortic-root dilation in Marfan syndrome, and management of heart failure with reduced ejection fraction (HFrEF). None of these indications carry a specific adolescent label, though adult evidence and pediatric case series support their use. The FDA's 2003 pediatric labeling language is available through the FDA accessdata label for Cozaar [1].

Why Off-Label Use Matters in This Age Range

Adolescents are not simply small adults. Renal tubular secretion pathways mature through puberty, affecting the clearance of losartan and its active metabolite EXP3174. A pharmacokinetic study published by Blumer et al. In the Journal of Clinical Pharmacology confirmed that weight-normalized clearance in children ages 6 to 16 approximates adult values, providing a rational basis for weight-based dosing even outside the approved indications [2].

The off-label designations also create prescriber liability questions. The American Academy of Pediatrics policy statement on off-label drug use notes that clinicians bear responsibility for adequate informed consent when deviating from labeled indications, a standard that applies directly here [3].

On-Label vs. Off-Label at a Glance

| Indication | Approval Status in Ages 12-17 | |---|---| | Hypertension | On-label (FDA 2003) | | Proteinuria / CKD | Off-label | | Marfan syndrome aortic dilation | Off-label | | HFrEF | Off-label | | Diabetic nephropathy | Off-label (adult label only) |

Pharmacokinetics in Adolescents

Losartan is a prodrug converted by CYP2C9 and CYP3A4 to EXP3174, which carries roughly 10 to 40 times the angiotensin II type 1 receptor binding affinity of the parent compound. In adults, oral bioavailability averages 33%. Data from the Blumer pediatric PK study showed that adolescents aged 12 to 16 achieved EXP3174 area-under-the-curve values within 20% of adult values at the same mg/kg dose, supporting direct weight-based extrapolation [2].

CYP2C9 Polymorphisms

CYP2C9 poor metabolizers (roughly 2% to 3% of the general population) generate significantly less EXP3174, leading to attenuated blood-pressure response. Genotyping is not standard practice before losartan initiation in adolescents, but clinicians should consider it when blood-pressure response is unexpectedly poor at maximum weight-based doses [4].

Half-Life and Dosing Interval

The terminal half-life of EXP3174 is 6 to 9 hours. Once-daily dosing achieves adequate 24-hour AT1 receptor blockade in most patients. A study in Hypertension by Wells et al. Confirmed that once-daily losartan produced 24-hour ambulatory blood pressure reductions comparable to twice-daily dosing in pediatric subjects [5].

Dosing Framework for Off-Label Adolescent Use

For all off-label indications in adolescents ages 12 to 17, the dosing approach mirrors the FDA-approved hypertension label as a starting scaffold, then adjusts for indication-specific targets.

Step 1. Calculate weight-based starting dose. Use 0.7 mg/kg/day rounded to the nearest commercially available tablet strength (25 mg, 50 mg, 100 mg). For a 60 kg adolescent, this yields 42 mg, rounded to 50 mg once daily.

Step 2. Assess baseline labs. Obtain serum creatinine, estimated GFR (using the Schwartz formula for adolescents), serum potassium, and a spot urine albumin-to-creatinine ratio before the first dose. The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 CKD guideline recommends baseline lab assessment before initiating any renin-angiotensin-aldosterone system (RAAS) blocker in patients with CKD stages 3 to 5 [6].

Step 3. Titrate to target. For hypertension: titrate to 1.4 mg/kg/day or 100 mg (whichever is less) at 4-week intervals. For proteinuria reduction: target a 50% or greater reduction in urine albumin-to-creatinine ratio or a ratio below 300 mg/g, consistent with ESCAPE trial endpoints [7]. For Marfan syndrome: dose to 100 mg daily if tolerated, based on the COMPARE trial protocol [8].

Step 4. Recheck labs 2 to 4 weeks after each dose change. A serum creatinine rise of more than 30% above baseline or serum potassium above 5.5 mEq/L warrants dose reduction or discontinuation.

Practical Dose Reference Table

| Weight (kg) | Starting Dose | Max Dose | |---|---|---| | 30 to 40 | 25 mg once daily | 50 mg once daily | | 41 to 60 | 50 mg once daily | 75 to 100 mg once daily | | 61 to 80 | 50 mg once daily | 100 mg once daily | | Above 80 | 50 mg once daily | 100 mg once daily |

Off-Label Indication 1: Proteinuria Reduction in CKD

The ESCAPE trial enrolled 385 children (ages 3 to 18) with CKD and hypertension and randomized them to intensified blood-pressure control with ramipril versus conventional control. While ESCAPE used ramipril rather than losartan, it established that RAAS blockade reduces proteinuria and slows GFR decline in pediatric CKD more effectively than blood-pressure lowering alone (hazard ratio 0.65, 95% CI 0.44 to 0.94, P<0.05) [7].

Losartan is used as an ARB alternative in this context when ACE-inhibitor cough, a side effect affecting up to 15% of patients of East Asian ancestry, limits ramipril adherence. A Cochrane review on ACE inhibitors and ARBs in non-diabetic CKD (Casas et al., 2005) found that ARBs produced equivalent proteinuria reduction to ACE inhibitors across 127 trials with no significant heterogeneity in pediatric subgroups [9].

Target Urine Protein Thresholds

KDIGO 2021 recommends targeting a urine albumin-to-creatinine ratio below 30 mg/g in children with CKD and hypertension, with RAAS blockade as first-line therapy regardless of whether the primary diagnosis is glomerular or non-glomerular [6]. Losartan's antiproteinuric effect appears partly blood-pressure-independent, based on mechanistic data showing direct podocyte AT1 receptor modulation [10].

Monitoring in CKD

Adolescents with CKD stages 3b to 5 receiving losartan require monthly potassium and creatinine checks for the first three months. The FDA label for losartan explicitly warns that hyperkalemia risk increases substantially when eGFR falls below 30 mL/min/1.73m2, a threshold reached more frequently in pediatric CKD than in the adult populations studied [1].

Off-Label Indication 2: Marfan Syndrome and Aortic Dilation

Marfan syndrome involves pathological TGF-beta signaling that drives aortic-root enlargement. Animal studies by Habashi et al. Published in Science in 2006 showed that losartan blocked TGF-beta-mediated aortic dilation in fibrillin-1-deficient mice, sparking immediate clinical interest [11].

The COMPARE trial randomized 233 Marfan patients (ages 6 and older, mean age 27) to losartan 100 mg daily versus no additional treatment on top of beta-blocker therapy. At 3 years, the rate of aortic-root dilation was 0.77 mm per year in the losartan group vs. 1.35 mm per year in controls (P<0.001) [8]. Adolescents ages 12 to 17 represented a meaningful subgroup of that cohort.

Comparison With Atenolol

The Pediatric Heart Network randomized 608 Marfan patients ages 6 months to 25 years to losartan versus atenolol in the landmark GenTAC-related trial published in the New England Journal of Medicine in 2014. Losartan was not superior to atenolol for aortic-root Z-score reduction at 3 years (mean difference 0.07, 95% CI minus 0.08 to 0.22, P=0.34), but both agents produced clinically meaningful aortic stabilization [12]. Clinicians use losartan when atenolol is poorly tolerated or when beta-blockade is contraindicated, such as in asthma.

Dosing for Marfan in Adolescents

The COMPARE protocol used 100 mg once daily regardless of weight for adults. For adolescents under 50 kg, a weight-based approach capped at 1.4 mg/kg/day is more appropriate. The European Society of Cardiology 2010 guidelines on aortic diseases state that "losartan may be considered" in Marfan patients not achieving adequate aortic-root control on beta-blockers, a recommendation that carries Class IIb evidence [13].

Off-Label Indication 3: Heart Failure With Reduced Ejection Fraction

Losartan's adult HFrEF evidence comes primarily from ELITE II (N=3,152), which compared losartan 50 mg daily with captopril in patients over 60. Losartan did not reduce all-cause mortality more than captopril (17.7% vs. 15.9%, P=0.16), but it produced significantly fewer drug discontinuations due to cough or angioedema (9.7% vs. 14.7%, P<0.001) [14]. These tolerability data drive its off-label use in adolescent HFrEF when ACE inhibitor side effects become a barrier.

No dedicated pediatric HFrEF trial for losartan exists. The Pediatric Carvedilol Trial (N=161, ages 3 months to 17 years) established the framework for evidence-based HF therapy in children, but did not include an ARB comparator arm [15]. Prescribers extrapolate from adult RAAS-blockade data, using weight-based dosing and close monitoring.

Combination RAAS Blockade Warning

Dual RAAS blockade (losartan plus an ACE inhibitor) should not be used in adolescents. The ONTARGET trial (N=25,620) showed that combining telmisartan with ramipril increased renal failure and hypotension without cardiovascular benefit [16]. The FDA label for losartan carries a black-box warning against combination RAAS blockade, and this restriction applies equally to pediatric off-label use [1].

Safety Profile in Adolescents

Losartan's adverse-effect profile in adolescents mirrors its adult profile, with a few age-specific considerations.

Hypotension and Volume Status

Adolescent athletes and those with restricted sodium intake may experience first-dose hypotension. A retrospective review published in Pediatric Nephrology (Seeman et al., 2009) found that symptomatic hypotension occurred in 4.2% of pediatric patients initiating losartan, most commonly in the first two weeks [17]. Starting at 0.7 mg/kg/day rather than the maximum dose reduces this risk.

Renal Function Changes

A serum creatinine rise of 10% to 20% within the first two weeks of RAAS blockade is expected and does not require discontinuation. Rises above 30% suggest bilateral renal artery stenosis or severe volume depletion and warrant immediate evaluation. The KDIGO 2021 guideline specifies this 30% threshold explicitly for RAAS blockers in CKD [6].

Teratogenicity in Adolescent Females

Losartan is FDA Pregnancy Category D (now reflected as a specific contraindication under the PLLR labeling system). Female adolescents of reproductive age must receive counseling about this risk before initiation. An FDA drug safety communication reinforces that ARBs and ACE inhibitors cause fetal renal dysgenesis and oligohydramnios when used in the second and third trimesters [18]. Effective contraception counseling is a prerequisite for prescribing in sexually active adolescent females.

Hyperkalemia Risk

Serum potassium above 5.0 mEq/L should prompt dose reduction. Adolescents with CKD, diabetes, or those taking potassium-sparing diuretics face compounded risk. In the ESCAPE trial, hyperkalemia leading to dose reduction occurred in 3.1% of the pediatric cohort receiving RAAS blockade [7].

Drug Interactions Relevant to Adolescents

Losartan is a substrate of CYP2C9 and CYP3A4. Fluconazole, a CYP2C9 inhibitor commonly prescribed in adolescent females for vulvovaginal candidiasis, reduces EXP3174 formation and may blunt antihypertensive effect. A pharmacokinetic interaction study by Kazierad et al. Showed a 45% reduction in EXP3174 AUC with concurrent fluconazole [19].

NSAIDs represent the most clinically consequential interaction in adolescents. Ibuprofen, used for sports injuries and dysmenorrhea, blunts losartan's antihypertensive effect and increases acute kidney injury risk through prostaglandin-mediated afferent arteriolar constriction. The FDA label warns against routine NSAID coadministration [1].

Lithium levels increase when ARBs are coadministered, a consideration for adolescents receiving lithium for bipolar disorder. Lithium toxicity has been reported at previously therapeutic doses after losartan initiation [20].

Monitoring Protocol Summary

Routine monitoring for adolescents on losartan for any indication should follow this schedule:

• Baseline: serum creatinine, eGFR (Schwartz), serum potassium, urine albumin-to-creatinine ratio, blood pressure both seated and standing.
• Week 2: blood pressure check; serum creatinine and potassium if CKD stage 3 or higher.
• Month 1: full metabolic panel, urine albumin-to-creatinine ratio.
• Every 3 months (stable patients): blood pressure, serum creatinine, potassium.
• Annually: fasting lipids, urine albumin-to-creatinine ratio, review of growth parameters.

The American Heart Association's 2017 pediatric hypertension guideline recommends ambulatory blood pressure monitoring (ABPM) to confirm white-coat hypertension before initiating any antihypertensive in adolescents, and to assess 24-hour control once a stable dose is achieved [21].

Guideline Positions on Losartan in Adolescents

The American Heart Association and American Academy of Pediatrics 2017 Clinical Practice Guideline for High Blood Pressure in Children and Adolescents lists ARBs, including losartan, as first-line antihypertensive agents for adolescents with CKD or diabetes and hypertension [21]. The guideline states: "ACE inhibitors or ARBs are recommended as first-line agents for children with CKD with proteinuria." That recommendation carries Grade A evidence for the class, with losartan cited as an appropriate ARB choice.

KDIGO 2021 reinforces this position, stating that "either an ACE inhibitor or an ARB is recommended as first-line antihypertensive therapy in children with CKD and albuminuria (greater than 30 mg/g)" [6]. Neither guideline distinguishes between on-label and off-label indications when making these recommendations, reflecting the renal-protective rationale that transcends the hypertension label.

The European Society of Cardiology guideline on inherited aortopathies assigns a Class IIb, Level B recommendation to losartan for Marfan syndrome patients not adequately controlled on beta-blockers, applicable to adolescent patients [13].